Biosimilars Blog
RF 360


Insightful. Precise. Skilled.

Steven Lieberman and Derek F. Dahlgren at the BIO Intellectual Property Counsels Committee Conference

Ethical Issues in the Pharmaceutical Industry, including in Hatch-Waxman and Biosimilar Litigations


March 27, 2017 — March 29, 2017

Rothwell Figg attorneys Steven Lieberman and Derek Dahlgren will participate in a panel during the Biotechnology Innovation Organization Intellectual Property Counsel Committee Conference (BIO-IPCC Spring Conference) being held March 27 - 29, 2017, in Newport Beach, CA.

The panel, titled "Ethical Issues in the Pharmaceutical Industry, including in Hatch-Waxman and Biosimilar Litigations," will discuss real-world ethical issues parties face in the pharmaceutical industry, with an emphasis on how those issues affect Hatch-Waxman and biosimilar litigation. This includes the anti-bribery provisions under the Foreign Corrupt Practices Act (including such issues as hiring the children of government officials), and those applicable to foreign firms and persons; privacy laws and data breaches; the use of private investigators and cybersleuthing (including the use of social media) of competitors and their key opinion leaders; off-label promotion; stricter clinical trial data reporting requirements; and patent applicants’ duty of disclosure to the Patent Office.  The panel will also discuss best practices for avoiding the many pitfalls facing companies in this industry.

The panel will be moderated by Rothwell Figg attorney Steven Lieberman, and will feature Ms. Li Westerlund, Vice President at Bavarian Nordic Inc. and Mr. Derek Dahlgren, attorney at Rothwell Figg.